Vaccination using peptides spanning the SYT-SSX tumor-specific translocation

Expert Review of Vaccines

Volumn 11, Issue 12, 2012, Pages 1401-1404

  Bloom, Jordan E ^a   McNeel, Douglas G ^a   Olson, Brian M ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

IFN ; peptide vaccine; SSX; synovial sarcoma; SYT; SYT SSX

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; K9I VACCINE; SS393 VACCINE; UNCLASSIFIED DRUG;

ADULT; AGED; BRAIN HEMORRHAGE; CANCER PREVENTION; CLINICAL ARTICLE; DRUG WITHDRAWAL; GENE TRANSLOCATION; HUMAN; IMMUNE RESPONSE; PRIORITY JOURNAL; REVIEW; SYNOVIAL SARCOMA;

EID: 84871554244     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.122     Document Type: Review

References (20)

1. Do K, Doroshow JH, Kummar S. Antiangiogenic approaches for the treatment of advanced synovial sarcomas. Curr. Opin. Oncol. 24(4), 425-430 (2012).
2. Sato Y, Nabeta Y, Tsukahara T et al. Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24(+) patients with synovial sarcoma. J. Immunol. 169(3), 1611-1618 (2002).
3. Ida K, Kawaguchi S, Sato Y et al. Crisscross CTL induction by SYT-SSX junction peptide and its HLA-A*2402 anchor substitute. J. Immunol. 173(2), 1436-1443 (2004).
4. Kawaguchi S, Wada T, Tsukahara T et al. A quest for therapeutic antigens in bone and soft tissue sarcoma. J. Transl. Med. 3, 31 (2005).
5. Kawaguchi S, Tsukahara T, Ida K et al. SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: a study from the Japanese Musculoskeletal Oncology Group. Cancer Sci. 103(9), 1625-1630 (2012).
6. Smith HA, McNeel DG. The SSX family of cancer-testis antigens as target proteins for tumor therapy. Clin. Dev. Immunol. 2010, 150591 (2010).
7. Cheever MA, Allison JP, Ferris AS et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res. 15(17), 5323-5337 (2009).
8. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50(3-4), 213-219 (1999).
9. Wang F, Bade E, Kuniyoshi C et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin. Cancer Res. 5(10), 2756-2765 (1999).
10. Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K, Knutson KL. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin. Cancer Res. 6(4), 1347-1350 (2000).
11. Salgaller ML, Lodge PA, McLean JG et al. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate 35(2), 144-151 (1998).
12. Brodowicz T, Wiltschke C, Kandioler-Eckersberger D et al. Inhibition of proliferation and induction of apoptosis in soft tissue sarcoma cells by interferon-alpha and retinoids. Br. J. Cancer 80(9), 1350-1358 (1999).
13. Wang JC, Livingstone AM. Cutting edge: CD4+ T cell help can be essential for primary CD8+ T cell responses in vivo. J. Immunol. 171(12), 6339-6343 (2003).
14. Ontiveros F, Wilson EB, Livingstone AM. Type I interferon supports primary CD8+ T-cell responses to peptide-pulsed dendritic cells in the absence of CD4+ T-cell help. Immunology 132(4), 549-558 (2011).
15. Smith HA, McNeel DG. Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells. J. Immunother. 34(8), 569-580 (2011).
16. Smith HA, Cronk RJ, Lang JM, McNeel DG. Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer. Cancer Res. 71(21), 6785-6795 (2011).
17. Janetzki S, Panageas KS, Ben-Porat L et al.; Elispot Proficiency Panel of the CVC Immune Assay Working Group. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol. Immunother. 57(3), 303-315 (2008).
18. Kantoff PW, Higano CS, Shore ND et al.; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010).
19. Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, Phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115(16), 3670-3679 (2009).
20. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immunerelated response criteria. Clin. Cancer Res. 15(23), 7412-7420 (2009).